BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17102117)

  • 1. Aspects on radionuclide therapy in malignant pheochromocytomas.
    Forssell-Aronsson E; Bernhardt P; Wängberg B; Kölby L; Nilsson O; Ahlman H
    Ann N Y Acad Sci; 2006 Aug; 1073():498-504. PubMed ID: 17102117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
    Troncone L; Rufini V
    Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
    Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
    Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
    Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas?
    Kölby L; Bernhardt P; Johanson V; Wängberg B; Muth A; Jansson S; Forssell-Aronsson E; Nilsson O; Ahlman H
    Ann N Y Acad Sci; 2006 Aug; 1073():491-7. PubMed ID: 17102116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic possibilities in metastatic pheochromocytoma].
    Vierhapper H; Raber W
    Zentralbl Chir; 1997; 122(6):494-7. PubMed ID: 9334119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
    Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
    Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete remission of metastatic pheochromocytoma in
    Sugino T; Ando R; Unno R; Iida K; Naiki T; Hamamoto S; Mizuno K; Okada A; Umemoto Y; Kawai N; Tozawa K; Hayashi Y; Inaki A; Kayano D; Kinuya S; Yasui T
    BMC Res Notes; 2017 Dec; 10(1):750. PubMed ID: 29258609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results of [131]metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma.
    Colombo L; Lomuscio G; Vignati A; Dottorini ME
    J Nucl Biol Med (1991); 1991; 35(4):300-4. PubMed ID: 1823841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-131-MIBG therapy of a patient with carcinoid liver metastases.
    Prvulovich EM; Stein RC; Bomanji JB; Ledermann JA; Taylor I; Ell PJ
    J Nucl Med; 1998 Oct; 39(10):1743-5. PubMed ID: 9776280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma.
    Lumbroso J; Schlumberger M; Tenenbaum F; Aubert B; Travagli JP; Parmentier C
    J Nucl Biol Med (1991); 1991; 35(4):288-91. PubMed ID: 1823838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of malignant pheochromocytoma using I-131 metaiodobenzylguanidine--report of a case].
    Okazawa H; Endo K; Saga T; Watanabe Y; Nakai T; Kasagi K; Konishi J; Abe M; Goto K; Nakao K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1990 Mar; 50(3):286-94. PubMed ID: 2345700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
    Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma.
    Lewington VJ; Zivanovic MA; Tristam M; McEwan AJ; Ackery DM
    J Nucl Biol Med (1991); 1991; 35(4):280-3. PubMed ID: 1823836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy.
    Castellani MR; Seghezzi S; Chiesa C; Aliberti GL; Maccauro M; Seregni E; Orunesu E; Luksch R; Bombardieri E
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):100-13. PubMed ID: 20168292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [131I]metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group.
    Troncone L; Rufini V; Daidone MS; De Santis M; Luzi S
    J Nucl Biol Med (1991); 1991; 35(4):295-9. PubMed ID: 1823840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nuclear medicine diagnosis and therapy of distant metastases of pheochromocytoma].
    Grünwald F; Ruhlmann J; Kozak B; Overlack A; Christ F; Hotze A; Biersack HJ
    Dtsch Med Wochenschr; 1988 Feb; 113(8):297-9. PubMed ID: 3277832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.
    Jungels C; Karfis I
    Curr Opin Oncol; 2021 Jan; 33(1):33-39. PubMed ID: 33093336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.